Lamivudine/zidovudine
mixture of chemical compounds
Lamivudine/zidovudine, sold under the brand name Combivir among others, is a fixed-dose combination antiretroviral medication used to treat HIV/AIDS. It contains two antiretroviral medications, lamivudine and zidovudine. It is used together with other antiretrovirals. It is taken by mouth twice a day.
Common side effects include headache, feeling tired, nausea, diarrhea, and fever. Severe side effects may include bone marrow suppression, muscle damage, worsening of hepatitis B if previously infected, high blood lactate and liver enlargement. It may be part of a recommended treatment during pregnancy. The medications are both of the nucleoside reverse transcriptase inhibitor (NRTI) class. They work by blocking the action of the enzyme, reverse transcriptase, that the virus requires to reproduce.
Lamivudine/zidovudine was approved for medical use in the United States in 1997, and in the European Union in 1998. It is on the World Health Organization's List of Essential Medicines.
This brief starts where responsible research should: with the source description of “Lamivudine/zidovudine” as mixture of chemical compounds. Everything that follows is an evidence route, not borrowed authority.
Why this record matters
The subject matters to the science & nature register because the source frames it as mixture of chemical compounds. Its deeper value depends on whether names, dates, institutions and citations support that framing.
Datasets, specimens, observations and peer-reviewed methods provide the appropriate test for the technical claims summarized here. The source revision retrieved here is dated Feb 16, 2026. The linked authority identifier is Q6482030. None of the 0 selected statements returned an explicit reference. The first chronological checks are 1997 and 1998.
Current terminology should not be projected backward without checking the classification used when the underlying evidence was created. The source lead contains qualifying language; that uncertainty should survive quotation, summary and reuse. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Check terminology, classification and the date of the cited evidence. Scientific names and technical consensus can change while older records retain historical value.
- Current terminology
- Classification context
- Finding cited technical literature
Primary datasets, specimen catalogues, standards bodies and the most recent peer-reviewed literature.
Three-step research path
- Establish the record: confirm the title “Lamivudine/zidovudine”, its source revision and the description used here.
- Expand the search: follow Lamivudine/zidovudine primary sources, Lamivudine/zidovudine archive and Lamivudine research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “Lamivudine/zidovudine”?
- Is the terminology current, historical or disputed?
- Which observation, specimen, dataset or publication supports the account?
Search terms from this dossier
This entry incorporates text from “Lamivudine/zidovudine” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.